HLA-J: A Potential Drug Target and Biomarker (G3137)

Target Name: HLA-J

NCBI ID: G3137

HLA-J

Other Name(s): MGC71446 | HLA-59 | HLA-CDA12 | Major histocompatibility complex, class I, J (pseudogene) | D6S203 | MGC105145 | CDA12 | major histocompatibility complex, class I, J (pseudogene)

HLA-J: A Potential Drug Target and Biomarker

HLA-J (MGC71446) is a human leukocyte antigen (HLA) class I molecule that is expressed in various tissues and cell types in the human body. HLA-J is a key molecule in the immune system, as it is the receptor for the T-cell receptor (TCR), which is responsible for triggering an immune response. Despite its importance in the immune system, HLA-J has also been identified as a potential drug target and biomarker.

Drug Target Potential

HLA-J is a protein that is expressed in the human body and is involved in the immune response. As a result, HLA-J has been identified as a potential drug target. One of the main reasons for its potential as a drug target is its involvement in the T-cell response. T-cells are a crucial part of the immune system, as they are responsible for recognizing and responding to foreign substances in the body. HLA-J is the receptor for the T-cell receptor, which is responsible for triggering an immune response.

In addition to its role in the T-cell response, HLA-J has also been shown to play a role in the regulation of inflammation. When the immune system is activated, HLA-J helps to regulate the production of inflammatory cytokines, which can contribute to the development of inflammatory diseases.

Biomarker Potential

HLA-J has also been identified as a potential biomarker for several diseases, including cancer, autoimmune diseases, and inflammatory diseases. One of the main reasons for its potential as a biomarker is its expression in various tissues and cell types in the human body. This makes it a reliable indicator of disease status, as the expression of HLA-J is often reduced in diseases such as cancer and autoimmune diseases.

In addition to its potential as a biomarker, HLA-J has also been shown to be involved in the regulation of immune cell function. For example, studies have shown that HLA-J plays a role in the regulation of T-cell proliferation and differentiation. This suggests that HLA-J may be a useful target for drugs that are designed to enhance or inhibit the immune system.

Conclusion

In conclusion, HLA-J is a human leukocyte antigen (HLA) class I molecule that is expressed in various tissues and cell types in the human body. Its involvement in the immune system and its potential as a drug target and biomarker make it an attractive target for research and development of new therapies. Further studies are needed to fully understand the role of HLA-J in the immune system and its potential as a drug and biomarker.

Protein Name: Major Histocompatibility Complex, Class I, J (pseudogene)

The "HLA-J Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-J comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets